GALECTIN THERAPEUTICS INC. Repayments of Convertible Debt
GALECTIN THERAPEUTICS INC. (GALT) reported Repayments of Convertible Debt of $1.64 million for the 165-month period ending 2014-03-31, per its 10-Q filed 2014-05-13.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfConvertibleDebt · last filed 2014-05-13
- GALECTIN THERAPEUTICS INC. repayments of convertible debt for the quarter ending 2014-03-31 was $0.00.
- GALECTIN THERAPEUTICS INC. repayments of convertible debt for the quarter ending 2013-12-31 was $0.00.
- GALECTIN THERAPEUTICS INC. repayments of convertible debt for the quarter ending 2013-09-30 was $0.00.
- GALECTIN THERAPEUTICS INC. repayments of convertible debt for the quarter ending 2013-06-30 was $0.00.
| Period end | Repayments of Convertible Debt 3 month | Repayments of Convertible Debt 6 month | Repayments of Convertible Debt 9 month | Repayments of Convertible Debt 12 month | Repayments of Convertible Debt 132 month | Repayments of Convertible Debt 135 month | Repayments of Convertible Debt 138 month | Repayments of Convertible Debt 141 month | Repayments of Convertible Debt 144 month | Repayments of Convertible Debt 147 month | Repayments of Convertible Debt 150 month | Repayments of Convertible Debt 153 month | Repayments of Convertible Debt 156 month | Repayments of Convertible Debt 159 month | Repayments of Convertible Debt 162 month | Repayments of Convertible Debt 165 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014-03-31 | $0.00 derived: 10-Q 165 month − 10-K 162 month · filed 2014-05-13 | $0.00 derived: sum of 2 quarters · filed 2014-05-13 | $0.00 derived: sum of 3 quarters · filed 2014-05-13 | $0.00 derived: sum of 4 quarters · filed 2014-05-13 | $1.64M 10-Q · filed 2014-05-13 | |||||||||||
| 2013-12-31 | $0.00 derived: 10-K 162 month − 10-Q 159 month · filed 2014-03-21 | $0.00 derived: sum of 2 quarters · filed 2014-03-21 | $0.00 derived: sum of 3 quarters · filed 2014-03-21 | $0.00 derived: sum of 4 quarters · filed 2014-03-21 | $1.64M 10-K · filed 2014-03-21 | |||||||||||
| 2013-09-30 | $0.00 derived: 10-Q 159 month − 10-Q 156 month · filed 2013-11-12 | $0.00 derived: sum of 2 quarters · filed 2013-11-12 | $0.00 derived: sum of 3 quarters · filed 2013-11-12 | $1.64M 10-Q · filed 2013-11-12 | ||||||||||||
| 2013-06-30 | $0.00 derived: 10-Q 156 month − 10-Q 153 month · filed 2013-08-14 | $0.00 derived: sum of 2 quarters · filed 2013-08-14 | $1.64M 10-Q · filed 2013-08-14 | |||||||||||||
| 2013-03-31 | $0.00 derived: 10-Q 153 month − 10-K 150 month · filed 2013-05-10 | $1.64M 10-Q · filed 2013-05-10 | ||||||||||||||
| 2012-12-31 | $1.64M 10-K · filed 2013-03-29 | |||||||||||||||
| 2012-09-30 | $0.00 derived: 10-Q 147 month − 10-Q 144 month · filed 2012-11-09 | $0.00 derived: sum of 2 quarters · filed 2012-11-09 | $0.00 derived: sum of 3 quarters · filed 2012-11-09 | $0.00 derived: sum of 4 quarters · filed 2012-11-09 | $1.64M 10-Q · filed 2012-11-09 | |||||||||||
| 2012-06-30 | $0.00 derived: 10-Q 144 month − 10-Q 141 month · filed 2012-08-10 | $0.00 derived: sum of 2 quarters · filed 2012-08-10 | $0.00 derived: sum of 3 quarters · filed 2012-08-10 | $0.00 derived: sum of 4 quarters · filed 2012-08-10 | $1.64M 10-Q · filed 2012-08-10 | |||||||||||
| 2012-03-31 | $0.00 derived: 10-Q 141 month − 10-K 138 month · filed 2012-05-11 | $0.00 derived: sum of 2 quarters · filed 2012-05-11 | $0.00 derived: sum of 3 quarters · filed 2012-05-11 | $1.64M 10-Q · filed 2012-05-11 | ||||||||||||
| 2011-12-31 | $0.00 derived: 10-K 138 month − 10-Q 135 month · filed 2012-03-30 | $0.00 derived: sum of 2 quarters · filed 2012-03-30 | $1.64M 10-K · filed 2012-03-30 | |||||||||||||
| 2011-09-30 | $0.00 derived: 10-Q 135 month − 10-Q 132 month · filed 2011-11-10 | $1.64M 10-Q · filed 2011-11-10 | ||||||||||||||
| 2011-06-30 | $1.64M 10-Q · filed 2011-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |